APA (7th ed.) Citation

JM, R., M, M., O, G., M, S., B, B., M, C., . . . JM, S. (2024). Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: Results of the BURKIMAB14 trial. Haematologica, 109(2), 543. https://doi.org/10.3324/haematol.2023.283342

Chicago Style (17th ed.) Citation

JM, Ribera, et al. "Feasibility and Outcomes After Dose Reduction of Immunochemotherapy in Young Adults with Burkitt Lymphoma and Leukemia: Results of the BURKIMAB14 Trial." Haematologica 109, no. 2 (2024): 543. https://doi.org/10.3324/haematol.2023.283342.

MLA (9th ed.) Citation

JM, Ribera, et al. "Feasibility and Outcomes After Dose Reduction of Immunochemotherapy in Young Adults with Burkitt Lymphoma and Leukemia: Results of the BURKIMAB14 Trial." Haematologica, vol. 109, no. 2, 2024, p. 543, https://doi.org/10.3324/haematol.2023.283342.